BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
6/15/2024 2:49:03 AM | Browse: 44 | Download: 232
 |
Received |
|
2023-12-11 07:07 |
|
Peer-Review Started |
|
2023-12-11 07:07 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2024-02-18 02:17 |
|
Revised |
|
2024-04-04 02:02 |
|
Second Decision |
|
2024-04-18 02:39 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2024-04-18 05:06 |
|
Articles in Press |
|
2024-04-18 05:06 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2024-05-14 12:37 |
|
Publish the Manuscript Online |
|
2024-06-15 02:49 |
| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Medicine, Research & Experimental |
| Manuscript Type |
Review |
| Article Title |
Advances in targeted therapy for human epidermal growth factor receptor 2 positive in advanced gastric cancer
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Ya-Kun Jiang, Wei Li, Ying-Yang Qiu and Meng Yue |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Meng Yue, MM, Doctor, Doctor, Department of Gastroenterology, Central Hospital Affiliated to Shandong First Medical University, No. 105 Jiefang Road, Jinan 250013, Shandong Province, China. mengtiger78@163.com |
| Key Words |
Human epidermal growth factor receptor 2; Gastric cancer; Targeted therapy; Review |
| Core Tip |
Human epidermal growth factor receptor 2 (HER2) is one of the most important targets in targeted therapy for gastric cancer. Trastuzumab combined with chemotherapy has been used as the first-line treatment for advanced gastric cancer. The safety and efficacy of pertuzumab and magtuximab in the treatment of gastric cancer have been verified. However, monoclonal antibodies, due to their large molecular weight, inability to penetrate the blood-brain barrier, and drug resistance, lead to decreased therapeutic efficacy, so it is necessary to explore the efficacy of other HER2-targeting therapies in gastric cancer. |
| Publish Date |
2024-06-15 02:49 |
| Citation |
<p>Jiang YK, Li W, Qiu YY, Yue M. Advances in targeted therapy for human epidermal growth factor receptor 2 positive in advanced gastric cancer . <i>World J Gastrointest Oncol</i> 2024; 16(6): 2318-2334</p> |
| URL |
https://www.wjgnet.com/1948-5204/full/v16/i6/2318.htm |
| DOI |
https://dx.doi.org/10.4251/wjgo.v16.i6.2318 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
